Nexus Pharmaceuticals announces launch of new injection

  • Nexus Pharmaceuticals Succinylcholine Chloride Injection, USP

    Nexus Pharmaceuticals Succinylcholine Chloride Injection, USP (Photo: Business Wire)

 
BUSINESS WIRE
Updated 4/12/2021 11:13 AM

Lincolnshire-based Nexus Pharmaceuticals announced the launch of Succinylcholine Chloride Injection, USP in 200mg/10mL multiple-dose vials. It is an AP-rated generic to Quelicin.

"The launch of Succinylcholine Chloride represents Nexus Pharmaceuticals' ability to supply critical products and to help fortify the supply chain," said Shahid Ahmed, Chief Scientific Officer of Nexus Pharmaceuticals.

 

"The COVID-19 pandemic deeply disrupted the supply of Succinylcholine Chloride, but Nexus' entry into the market will help alleviate constraints and provide peace of mind for our clinical partners."

Nexus Pharmaceuticals' Succinylcholine Chloride Injection is available in cartons of 25 vials.

Succinylcholine Chloride Injection, USP is a sterile, nonpyrogenic solution to be used as an ultra-short-acting, depolarizing, skeletal muscle relaxant. Succinylcholine is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

0 Comments
                                                                                                                                                                                                                       
 
Article Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.